Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer

Cancer Research

Volumn 70, Issue 14, 2010, Pages 5807-5817

  Lin, Ruo Kai ^a   Wu, Chiu Yi ^a   Chang, Jer Wei ^a   Juan, Li Jung ^c   Hsu, Han Shui ^d   Chen, Chih Yi ^f   Lu, Yun Yueh ^c   Tang, Yen An ^b   Yang, Yi Chieh ^a   Yang, Pan Chyr ^e   Wang, Yi Ching ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^f CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA METHYLTRANSFERASE 1; FRAGILE HISTIDINE TRIAD PROTEIN; PROTEIN MDM2; PROTEIN P53; RAB PROTEIN; RAB37 PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RETINOID X RECEPTOR BETA; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG;

ARTICLE; CARCINOGENESIS; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME REGULATION; EPIGENETICS; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION; TRANSCRIPTION INITIATION; UBIQUITINATION; WILD TYPE;

5-METHYLCYTOSINE; BINDING SITES; CELL LINE, TUMOR; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOPRECIPITATION; LUNG NEOPLASMS; POINT MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-MDM2; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 77955015091     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4161     Document Type: Article

References (40)

1. Esteller M. Dormant hypermethylated tumour suppressor genes: questions and answers. J Pathol 2005;205:172-80.
2. Momparler RL. Cancer epigenetics. Oncogene 2003;22: 6479-83.
3. Rauch TA, Zhong X, Wu X, et al. High-resolution mapping of DNA hypermethylation and hypomethylation in lung cancer. Proc Natl Acad Sci U S A 2008;105:252-7.
4. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 2004;429: 457-63.
5. Jamaluddin MS, Yang X, Wang H. Hyperhomocysteinemia, DNA methylation and vascular disease. Clin Chem Lab Med 2007;45: 1660-6.
6. Costa E, Dong E, Grayson DR, et al. Reviewing the role of DNA (cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics 2007;2:29-36.
7. Kanai Y. Alterations of DNA methylation and clinicopathological diversity of human cancers. Pathol Int 2008;58:544-58.
8. Abdolmaleky HM, Smith CL, Faraone SV, et al. Methylomics in psychiatry: modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet B Neuropsychiatr Genet 2004;127B:51-9.
9. Rhee I, Bachman KE, Park BH, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature 2002;416: 552-6.
10. Milutinovic S, Brown SE, Zhuang Q, Szyf M. DNMT1 knockdown induces gene expression by a mechanism independent of the two epigenetic silencing mechanisms: DNA methylation and histone deacetylation. J Biol Chem 2004;15:15.
11. Fatemi M, Hermann A, Gowher H, Jeltsch A. Dnmt3a and Dnmt1 functionally cooperate during de novo methylation of DNA. Eur J Biochem 2002;269:4981-4.
12. De Marzo AM, Marchi VL, Yang ES, et al. Abnormal regulation of DNA methyltransferase expression during colorectal carcinogenesis. Cancer Res 1999;59:3855-60.
13. Lin RK, Hsu HS, Chang JW, et al. Alteration of DNA methyltransferases contributes to 5′CpG methylation and poor prognosis in lung cancer. Lung Cancer 2007;55:205-13.
14. Girault I, Tozlu S, Lidereau R, Bieche I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin Cancer Res 2003;9:4415-22.
15. Saito Y, Kanai Y, Nakagawa T, et al. Increased protein expression of DNA methyltransferase (DNMT) 1 is significantly correlated with the malignant potential and poor prognosis of human hepatocellular carcinomas. Int J Cancer 2003;105:527-32.
16. Etoh T, Kanai Y, Ushijima S, et al. Increased DNA methyltransferase 1 (DNMT1) protein expression correlates significantly with poorer tumor differentiation and frequent DNA hypermethylation of multiple CpG islands in gastric cancers. Am J Pathol 2004; 164:689-99.
17. Mizuno S, Chijiwa T, Okamura T, et al. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 2001;97: 1172-9.
18. Peterson EJ, Bogler O, Taylor SM. p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. Cancer Res 2003;63:6579-82.
19. Guo Z, Tsai MH, Shiao YH, et al. DNA (cytosine-5)-methyltransferase 1 as a mediator ofmutant p53-determined p16(ink4A) down-regulation. J Biomed Sci 2008;15:163-8.
20. Esteve PO, Chin HG, Pradhan S. Molecular mechanisms of transactivation and doxorubicin-mediated repression of survivin gene in cancer cells. J Biol Chem 2007;282:2615-25.
21. St Clair S, Manfredi JJ. The dual specificity phosphatase Cdc25C is a direct target for transcriptional repression by the tumor suppressor p53. Cell Cycle 2006;5:709-13.
22. Innocente SA, Lee JM. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription. FEBS Lett 2005;579: 1001-7.
23. Sengupta S, Shimamoto A, Koshiji M, et al. Tumor suppressor p53 represses transcription of RECQ4 helicase. Oncogene 2005;24: 1738-48.
24. Dhar SK, Xu Y, Chen Y, St Clair DK. Specificity protein 1-dependent p53-mediated suppression of human manganese superoxide dismutase gene expression. J Biol Chem 2006;281: 21698-709.
25. Kishikawa S, Murata T, Kimura H, Shiota K, Yokoyama KK. Regulation of transcription of the Dnmt1 gene by Sp1 and Sp3 zinc finger proteins. Eur J Biochem 2002;269:2961-70.
26. Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 2000;60: 6788-93.
27. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009;137: 609-22.
28. Liu S, Liu Z, Xie Z, et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-κB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008;111:2364-73.
29. The PROMO online tool is available for download for academic and non-commercial use at: http://alggen.lsi.upc.es/.
30. The TFSEARCH online tool for searching transcription factor binding sites is available at http://www.cbrc.jp/research/db/TFSEARCH.html.
31. Wang YC, Chen CY, Chen SK, et al. High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan. Cancer Res 1998;58:328-33.
32. Leu YW, Rahmatpanah F, Shi H, et al. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer Res 2003;63:6110-5.
33. Tzao C, Tsai HY, Chen JT, Chen CY, Wang YC. 5′CpG island hypermethylation and aberrant transcript splicing both contribute to the inactivation of the FHIT gene in resected non-small cell lung cancer. Eur J Cancer 2004;40:2175-83.
34. Courey AJ, Holtzman DA, Jackson SP, Tjian R. Synergistic activation by the glutamine-rich domains of human transcription factor Sp1. Cell 1989;59:827-36.
35. Wu CY, Tseng RC, Hsu HS, Wang YC, Hsu MT. Frequent down-regulation of hRAB37 in metastatic tumor by genetic and epigenetic mechanisms in lung cancer. Lung Cancer 2009;63: 360-7.
36. Kim JS, Kim H, Shim YM, et al. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis 2004;25:2165-71.
37. Kim DH, Kim JS, Ji YI, et al. Hypermethylation of RASSF1A promoter is associated with the age at starting smoking and a poor prognosis in primary non-small cell lung cancer. Cancer Res 2003; 63:3743-6.
38. Johnson-Pais T, Degnin C, Thayer MJ. pRB induces Sp1 activity by relieving inhibition mediated by MDM2. Proc Natl Acad Sci U S A 2001;98:2211-6.
39. Lagger G, Doetzlhofer A, Schuettengruber B, et al. The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. Mol Cell Biol 2003;23:2669-79.
40. Vassilev LT, Vu BT, Graves B, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004;303: 844-8.